Incorporating proteomics into sarcoma research: where do we stand?
Proteomic research on sarcomas is only in its infancy, but it offers potential in terms of improved biological understanding, identification of new treatment targets and generating biomarkers for patient selection and prognosis prediction
What level of evidence do we need for drug approval in rare cancers?
Achieving clarity in levels of clinical evidence required by regulatory bodies is still a major obstacle to expediting research in the field, says Prof. Paolo G. Casali from the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and the University of Milan, Italy
Molecular management of metastatic GIST – challenges and opportunities
Thanks to remarkable advances, molecular analysis has taken central stage in the management of GIST, but there is still a need for less costly testing and further development of mitigation strategies to overcome resistance
What is on the horizon for the management of osteosarcoma?
2021 ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guidelines open the door to genetic testing but the search for new treatments continues
Is there a future for immunotherapy in sarcoma?
Continued efforts in patient selection, combination strategies and novel approaches may help to turn the tide for immunotherapeutics in sarcoma, according to Prof. Jean-Yves Blay
Single-agent doxorubicin – is it still the standard first-line therapy for all soft tissue sarcoma subtypes?
In practice, doxorubicin alone is often not used as the first-line standard of care for soft tissue sarcomas; however, a lack of high-quality survival data precludes other regimens becoming the gold standard
A new immunotherapy-based combination is promising in nasopharyngeal cancer
Tislelizumab in combination with gemcitabine and cisplatin prolonged PFS compared with chemotherapy alone in the RATIONALE 309 study
Are amplifying RNA vaccines the way forward for CAR-T-cell therapy?
Early clinical findings with the anti-claudin-6 CAR-T-cell product BNT211, with or without amplifying vaccine, in patients with refractory solid tumours are promising but more data are required
Can ctDNA changes after neoadjuvant therapy inform management of early NSCLC?
A study associates reductions in ctDNA with major pathologic response following neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC, but clinical application is still some way off
Can we further define patient groups who benefit from immunotherapy in advanced NSCLC?
Sub-group analyses of CheckMate 227 part 1 provide reassurance but no definite guidance regarding standard treatment for different patient sub-groups